



*Producers of Quality
Nonprescription Medicines and
Dietary Supplements for Self-Care*

CONSUMER HEALTHCARE PRODUCTS ASSOCIATION

Formerly Nonprescription Drug Manufacturers Association

November 5, 1999

Docket Management Branch (99N-4235)
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20852

**RE: Docket No. 99N-4235: Agency Emergency Processing Under OMB Review;
Survey of Manufacturing Practices in the Dietary Supplement Industry**

TO WHOM IT MAY CONCERN:

The Consumer Healthcare Products Association (CHPA) is submitting these comments, in response to the Food and Drug Administration (FDA) notice that appeared in the October 6, 1999 issue of the Federal Register (Volume 64, Number 193). In this notice, FDA is proposing to conduct a survey of manufacturing practices of dietary supplement establishments. The objectives of this survey, as stated, are to help FDA learn about the existing practices and to help formulate a policy to ensure that dietary supplements are produced under conditions that will minimize safety problems resulting from manufacturing without imposing unnecessary costs to the industry. The survey will also provide FDA with an understanding of the economic impact that any proposal to establish current good manufacturing practice (CGMP) regulations will have on both large and small firms in the dietary supplement industry.

CHPA is a 118-year-old trade organization representing producers of quality nonprescription medicines and dietary supplements. CHPA has over 200 members across the manufacturing, distribution, and service sectors of the self-care industry.

As indicated in comments filed with FDA on September 30, CHPA would like to see CFSAN place publication of ANPR for dietary supplement GMPs as a top priority in 2000. In addition, as communicated at the meeting on June 30, 1999, between members of CHPA's Dietary Supplements Strategic Planning Group and CFSAN, CHPA would like to assist FDA with the development of these GMPs. At this meeting, CFSAN explained that

... continued

99N-4235


C 1

site visits to DS manufacturing facilities would help the agency in its development of a proposed rule on GMPs. In response to this request, four CHPA member companies agreed at the meeting to work with CFSAN in organizing site visits to their facilities. These site visits took place in September 1999 and from feedback we received, the experience was very productive for both FDA and our member companies.


In regard to the proposed FDA survey of manufacturing practices in dietary supplement establishments, at the request of CHPA we received a copy of this survey and draft supporting statement from Peggy Schlosburg at the FDA. Having read the survey and draft supporting statement, we are of the opinion given the nature of some questions in the survey, manufacturers may choose not to respond rather than turn in an incomplete survey. Because of this action, FDA may not get the response it is expecting; i.e. 400 completed surveys or a 55% response rate. To encourage CHPA members to provide feedback to FDA on its October 6 Federal Register notice and survey, we mailed a copy of the survey and draft supporting statement to members representing the dietary supplement industry.

In conclusion, as indicated in comments CHPA filed with FDA on CFSAN's program priorities for the year 2000, we would like to see CFSAN place safety first – enforcement, GMPs and AERs when setting its priorities for program activities in the year 2000. Specifically, publication of ANPR for dietary supplement GMPs and having in place an effective and visible enforcement program. Further, rather than provide for special allowances for small firms in the dietary supplement industry in the GMPs for dietary supplements, we recommend that FDA extend the date by which these companies should comply with the regulation. Again, CHPA would like to extend its hand to assist FDA in drafting the proposed rule for dietary supplement GMPs. Please do not hesitate to contact either of us should FDA require additional assistance in refining the draft GMPs for dietary supplements.

Sincerely yours,



R. William Soller, Ph.D.
Senior Vice President and
Director of Science & Technology



Leila Saldanha, Ph.D., R.D.
Vice President – Nutritional Sciences

FedEx USA Airbill

FedEx
Tracking
Number

8156 6470 5610

1 From This portion can be removed for Recipient's records.

Date 11-5-99

FedEx Tracking Number

815664705610

Sender's
Name

Leila G. Saldanha, Ph.D. Phone 202 429-9260

Company CONSUMER HEALTHCARE PROD ASSN

Address 1150 CONNECTICUT AVE STE 1200

City WASHINGTON

State DC

ZIP 20036

RECIPIENT: PEEL HERE

2 Your Internal Billing Reference

DS

3 To

Recipient's
Name

Dockets Management Branch Phone 301 827-6860

Company FBod and Drug Administration

Address 5630 Fishers Ln.

Rm. 1061

We cannot deliver to P.O. boxes or P.O. ZIP codes.

To "HOLD" at FedEx location,
print FedEx address here.

City Rockville

State MD

ZIP 20852



0113806942

4a Express Package Service

☒ FedEx Priority Overnight
Next business morning

☐ FedEx Standard Overnight
Next business afternoon

☐ FedEx 2Day*
Second business day

☐ FedEx Express Save
Third business day

4b Express Freight Service

☐ FedEx 1Day Freight*
Next business day

☐ FedEx 2Day Freight
Second business day

* Call for Confirmation

5 Packaging

☒ FedEx Letter*

☐ FedEx Pak*

6 Special Handling

☐ Saturday Delivery
Available for FedEx Priority
Overnight and FedEx 2Day
to select ZIP codes

☐ Sunday Delivery
Available for FedEx Priority
Overnight to select ZIP codes

☐ HOLD
at FedEx
Not available
FedEx First

Does this shipment contain dangerous goods?

One box must be checked.

☒ No

☐ Yes

As per attached
Shipper's Declaration

☐ Yes

Shipper's Declaration
not required

☐ I
D

Dangerous Goods cannot be shipped in FedEx packaging.

7 Payment Bill to:

Enter FedEx Acct. No. or Credit Card No. below

☒ Sender
Acct. No. in Section
I will be billed.

☐ Recipient

☐ Third Party

Total Packages

Total Weight

1

*Our liability is limited to \$100 unless you declare a higher value. See the FedEx Service.

8 Release Signature

Sign to authorize delivery without obtaining signature

By signing you authorize us to deliver this shipment without obtaining a signature and agree to indemnify and hold us harmless from any resulting claims.

Questions? Call 1-800-Go-FedEx (800-463-3339)

Visit our Web site at www.fedex.com

SRS 796 • Rev. Date 11/98 • Part #154813S • ©1994-98 FedEx • PRINTED IN U.S.A.